A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Schones, Dustin E., Ph.D. Laboratory Bookmark and Share

Laboratory of Dustin E. Schones, Ph.D.

Our lab is generally interested in the role of chromatin in gene regulation and how other regulatory elements interact with chromatin. In addition to this, we are interested in how genetic variation interacts with epigenetic variation in the development of diseases such as diabetes and cancer. We utilize an integrative approach, combining experimental and computational methods, to study these problems.
 
One area of the lab is focused on the basic biology of mechanisms responsible for regulating chromatin architecture. We have identified characteristic chromatin patterns at functional regulatory regions of the genome, including promoter and distal enhancer regions. We are furthermore tracking changes in nucleosome positions along various lineage commitment pathways and investigating what mechanisms are responsible for regulating chromatin changes as well as how the changes in chromatin influence other regulatory events.
 
In addition, we are exploring the interaction of epigenetic and genetic variation in mouse models of cancer and diabetes. Genome-wide profiles of chromatin modifications, transcription factor binding, transcript production and genetic variation all provide one-dimensional views of genome regulation. To truly understand the regulatory networks involved in normal development – and how these networks are disrupted in disease progression – we must begin to integrate these data sets. Our results indicate that changes in chromatin accessibility cooperate with genetic variation to influence phenotypes. We are developing methods to integrate genotype, gene expression and chromatin information in prediction of phenotype. Furthermore, we are using these data from model systems to evaluate the potential of obtaining relevant genotype information from chromatin accessibility profiling. We anticipate these methods will be of practical use for personalized medicine in the clinic.
 
 
For more information on Dr. Schones, please click here.

Dustin Schones, Ph.D. Lab Members

Lab Members:
 
Beisi Xu, Ph.D.
Postdoctoral Fellow
626-256-4673, ext. 63300
beixu@coh.org
 
Juan Du
Grad Student
626-256-4673 ext. 64521
jdu@coh.org
 
Candi Trac, M.S.
Research Associate II
626-256-4673, ext. 64521
ctrac@coh.org

Schones, Dustin E., Ph.D. Laboratory

Laboratory of Dustin E. Schones, Ph.D.

Our lab is generally interested in the role of chromatin in gene regulation and how other regulatory elements interact with chromatin. In addition to this, we are interested in how genetic variation interacts with epigenetic variation in the development of diseases such as diabetes and cancer. We utilize an integrative approach, combining experimental and computational methods, to study these problems.
 
One area of the lab is focused on the basic biology of mechanisms responsible for regulating chromatin architecture. We have identified characteristic chromatin patterns at functional regulatory regions of the genome, including promoter and distal enhancer regions. We are furthermore tracking changes in nucleosome positions along various lineage commitment pathways and investigating what mechanisms are responsible for regulating chromatin changes as well as how the changes in chromatin influence other regulatory events.
 
In addition, we are exploring the interaction of epigenetic and genetic variation in mouse models of cancer and diabetes. Genome-wide profiles of chromatin modifications, transcription factor binding, transcript production and genetic variation all provide one-dimensional views of genome regulation. To truly understand the regulatory networks involved in normal development – and how these networks are disrupted in disease progression – we must begin to integrate these data sets. Our results indicate that changes in chromatin accessibility cooperate with genetic variation to influence phenotypes. We are developing methods to integrate genotype, gene expression and chromatin information in prediction of phenotype. Furthermore, we are using these data from model systems to evaluate the potential of obtaining relevant genotype information from chromatin accessibility profiling. We anticipate these methods will be of practical use for personalized medicine in the clinic.
 
 
For more information on Dr. Schones, please click here.

Lab Members

Dustin Schones, Ph.D. Lab Members

Lab Members:
 
Beisi Xu, Ph.D.
Postdoctoral Fellow
626-256-4673, ext. 63300
beixu@coh.org
 
Juan Du
Grad Student
626-256-4673 ext. 64521
jdu@coh.org
 
Candi Trac, M.S.
Research Associate II
626-256-4673, ext. 64521
ctrac@coh.org
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • The physical side effects of cancer can damage anyone’s self-confidence, but especially that of women who, rightly or wrongly, are more likely to find their appearance (or their own perception of their appearance) directly connected to their ability to face the world with something resembling aplomb. Furt...
  • The promise of stem cell therapy has long been studied in laboratories. Now, as medicine enters an era in which this therapy will be increasingly available to patients, the nurses who help deliver it will be in the spotlight. City of Hope, which has launched its Alpha Clinic for Cell Therapy and Innovation (ACT...
  • Just because you can treat a condition, such as high cholesterol, at the end of life — well, that doesn’t mean you should. That’s the basic lesson of a study to be published March 30 in JAMA Internal Medicine. The ramifications go far beyond that. The research, in which City of Hope’s Betty Fe...
  • The understanding of the relationship between genetics and cancer risk continues to grow, with more genetic testing than ever before available to patients. However, the adage that a little knowledge is a dangerous thing is applicable: Without context for what a test result means, and without meaningful guidance...
  • Standard prostate biopsies haven’t changed significantly in the past 30 years – nor have the problems inherent with them. Regular biopsies have an expected error rate: Tumors may potentially be undersampled and, 30 percent of the time, men who undergo a radical prostatectomy are found to have more aggress...
  • In the field of cancer, patients have had surgery, chemotherapy and radiation therapy as options. Now, as City of Hope officially opens the Alpha Clinic for Cellular Therapy and Innovation, patients battling cancer and other life-threatening diseases have another option: stem-cell-based therapy. The Alpha Clini...
  • How does the environment affect our health? Specifically, how does it affect our risk of cancer? City of Hope physicians and researchers recently answered those questions in an Ask the Experts event in Corona, California, explaining the underlying facts about how the environment can affect our health. Moderator...
  • Nurses and other medical professionals have come to understand that it’s not enough just to fight disease. They also must provide pain relief, symptom control, and an unrelenting commitment to improve patients’ quality of life — especially at the end of life. Not too long ago, this was a relatively ...
  • “Tonight, I’m launching a new precision medicine initiative to bring us closer to curing diseases like cancer.” These were the words of President Barack Obama on Jan. 20, 2015, during his State of the Union address. So what is precision medicine, and how close are we to making it a reality for...
  • March is Colon Cancer Awareness Month. How sad, yet how serendipitous, that the co-creator of “The Simpsons” Sam Simon passed away in March after a four-year battle against colon cancer. What message can we all learn from his illness that can help us prevent and overcome colon cancer in our own lives? Colon can...
  • Misagh Karimi, M.D., assistant clinical professor, is a medical oncologist at one of City of Hope’s newest community practice locations, located in Corona in Riverside County. A recent community health report from Corona’s public health department stated that obesity rates for teens and adults in Riverside Coun...
  • In 1975, the median survival for patients with ovarian cancer was about 12 months. Today, the median survival is more than 5 years. Although researchers and clinicians are far from satisfied, the progress in ovarian cancer treatment is encouraging, said Robert Morgan, M.D., F.A.C.P., professor of medical oncolo...
  • Colorectal cancer may be one of the most common cancers in both men and women, but it’s also one of the most curable cancers. Today, because of effective screening tests and more advanced treatment options, there are more than 1 million survivors of colorectal cancer in the United States. Here, colorectal...
  • Breast cancer treatment can damage a woman’s ability to become pregnant, making the impact on fertility one of the key factors that many consider when choosing a therapy regimen. Now a study has found that breast cancer patients treated with a hormone-blocking drug in addition to chemotherapy were less li...
  • My colleagues in the clinic know I’ve got a soft spot. Last week, a patient of mine offered me a fantastic compliment. “You’re looking younger these days, Dr. Pal!” she said, offering me a big hug as she proceeded out of the clinic room. Lovely, I thought. The early morning workouts are paying off. She continue...